ARLINGTON, Mass., Nov. 2, 2026 /PRNewswire/ -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a clinical-stage biopharmaceutical company developing exaluren for the treatment of rare kidney diseases, today announced that
FDA clearance of the IND enables Eloxx to open U.S. clinical sites for EXPRESS, its global Phase 2 study of exaluren in nonsense-mutation ADPKDEXPRESS will randomize approximately 60 patients 1:1 to exaluren or placebo
EXPRESS Phase 2 design finalized: 52 weeks of dosing of approximately 60 patients randomized 1:1 to exaluren or placebo, with annualized htTKV growth as the primary endpointSubstantial, durable htTKV effect could
Mr. Germano brings more than 35 years of biopharmaceutical leadership experience, including as Group President of Pfizer's Global Innovative Pharmaceutical businessExtensive public company board experience,
First two patients dosed in the EXACT studyTopline data from the initial 16-week placebo-controlled portion of the study expected mid-2027; final readout expected by the end of 2027ARLINGTON, Mass., Sept. 11, 2026
Completed underwritten public offering with gross proceeds of $66.0 million and uplisting to the Nasdaq Capital Market, significantly strengthening the Company's balance sheetPhase 2b clinical trial of exaluren in
ARLINGTON, Mass., June 8, 2026 /PRNewswire/ -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) ("Eloxx" and the "Company"), a clinical-stage biopharmaceutical company developing novel, small molecule product
Data from Eloxx's proof-of-concept trial in patients with nonsense mutation Alport Syndrome (NMAS) presented in late-breaking presentation at American Society of Nephrology (ASN) Kidney Week New protein analyses confirm
First two subjects dosed in Phase 1 clinical trial of ZKN-013; ZKN-013 is being developed for the potential treatment of rare dermatological and other diseases associated with nonsense mutations Positive written FDA
ELX-02 Granted Orphan Drug Designation (ODD) from U.S. Food and Drug Administration (FDA) for Treatment of Alport Syndrome Pre-Investigational New Drug (IND) Meeting Requested with U.S. FDA for ELX-02 to Discuss
Almirall obtains exclusive global rights to develop and commercialize ZKN-013 for the treatment of rare dermatological and other diseases associated with nonsense mutationsZKN-013 is a phase I ready oral therapy designed
Almirall obtains exclusive global rights to develop and commercialize ZKN-013 for the treatment of rare dermatological and other diseases associated with nonsense mutations
ZKN-013 is a phase I ready oral therapy
Kidney morphology improved in all three patients with protein re-expression consistent with disease regression in its Phase 2 open-label clinical trial of ELX-02 for the treatment of Alport Syndrome ELX-02 improved
Cognito Therapeutics, a pioneer developing disease-modifying therapeutics to treat CNS diseases, today announced the appointment of Greg Weaver as Chief Financial Officer (CFO), to lead all finance-related and investor
ELX-02 treatment improved podocyte foot process effacement in all three patients by an average of 60% based on a blinded kidney biopsy analysis by NIPOKA GmbH Biopsy results support clinical benefit in all three
